Africa pharmaceuticals market seen reaching $44.1B by 2032

By AI, Created 10:16 AM UTC, June 03, 2026, /AGP/ – Africa’s pharmaceuticals market is projected to grow from $29.3 billion in 2025 to $44.1 billion by 2032, driven by healthcare investment, local manufacturing and rising demand for affordable medicines. The report points to stronger supply chains and broader treatment access as key growth factors across the continent.

Why it matters: - The Africa pharmaceuticals market is expanding as governments and private groups invest more in healthcare infrastructure. - Faster growth in medicines access could improve treatment availability for infectious diseases, chronic conditions and other rising health needs. - Local production gains may reduce import dependence and help stabilize supply and pricing.

What happened: - Persistence Market Research said the Africa pharmaceuticals market will be worth $29.3 billion in 2025 and reach $44.1 billion by 2032. - The report pegs the forecast at a 6.1% compound annual growth rate. - The report covers prescription medicines, over-the-counter products, generic drugs, vaccines and specialty pharmaceuticals. - The report also outlines market segments by end user, including hospitals, clinics, retail pharmacies and healthcare institutions.

The details: - Demand is rising for prescription medicines, generic drugs, vaccines and specialty therapies as healthcare systems expand. - Generic medicines hold the largest share because of lower cost and easier access. - Prescription drugs continue to see strong demand as chronic disease rates rise and healthcare access widens. - Hospitals remain the biggest buyers because of higher patient volumes and better infrastructure. - Retail pharmacy expansion is improving access in urban and semi-urban areas. - Southern Africa leads the region because of stronger healthcare systems, pharmaceutical production capacity and more developed regulation. - East and West Africa are expanding quickly as healthcare spending rises and medicine imports increase. - The report lists Pfizer, Novartis, Sanofi, GlaxoSmithKline, Aspen Pharmacare, Cipla, Abbott, Bayer, Roche and AstraZeneca among key companies. - Free report sample is available from Persistence Market Research. - Customization options are available for the report. - The full report is available for purchase.

Between the lines: - The forecast reflects a market where affordability matters as much as access. - Local manufacturing, better distribution and public-private partnerships appear to be the main levers for growth. - Infrastructure gaps, rural access problems and fragmented regulation still slow adoption in many markets. - Import dependence keeps pricing vulnerable to supply disruptions and raw-material volatility.

What’s next: - Governments are expected to keep expanding healthcare programs and medicine-access initiatives. - Pharmaceutical companies may increase investment in local production facilities and distribution networks. - Digital pharmacies and telemedicine platforms are likely to play a bigger role in access expansion. - More collaboration between governments and drugmakers could accelerate market growth across the continent.